Trial · NCT01481116
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in HbA1c at Weeks 78 and 104 | Glimepiride | Baseline | 8.00 | Standard Error 0.814 | percentage of glycosylated hemoglobin |
| Change From Baseline in HbA1c at Weeks 78 and 104 | TAK-875 25 mg | Baseline | 8.01 | Standard Error 0.777 | percentage of glycosylated hemoglobin |
| Change From Baseline in HbA1c at Weeks 78 and 104 | TAK-875 50 mg | Baseline | 7.99 | Standard Error 0.792 | percentage of glycosylated hemoglobin |
| Change From Baseline in HbA1c at Weeks 78 and 104 | Glimepiride | Change at Week 78 | -0.80 | Standard Error 0.957 | percentage of glycosylated hemoglobin |
| Change From Baseline in HbA1c at Weeks 78 and 104 | TAK-875 25 mg | Change at Week 78 | -0.82 | Standard Error 0.865 | percentage of glycosylated hemoglobin |
| Change From Baseline in HbA1c at Weeks 78 and 104 | TAK-875 50 mg | Change at Week 78 | -0.98 | Standard Error 0.834 | percentage of glycosylated hemoglobin |
| Change From Baseline in HbA1c at Weeks 78 and 104 | Glimepiride | Change at Week 104 | NA | Standard Error NA | percentage of glycosylated hemoglobin |
| Change From Baseline in HbA1c at Weeks 78 and 104 | TAK-875 25 mg | Change at Week 104 | -1.03 | Standard Error 1.159 | percentage of glycosylated hemoglobin |
| Change From Baseline in HbA1c at Weeks 78 and 104 | TAK-875 50 mg | Change at Week 104 | 0.03 | Standard Error 0.603 | percentage of glycosylated hemoglobin |
| Percentage of Participants With Hypoglycemia | Glimepiride | Day 1 up to Week 78 | 30.2 | percentage of participants | |
| Percentage of Participants With Hypoglycemia | TAK-875 25 mg | Day 1 up to Week 78 | 5.4 | percentage of participants | |
| Percentage of Participants With Hypoglycemia | TAK-875 50 mg | Day 1 up to Week 78 | 5.3 | percentage of participants | |
| Percentage of Participants With Hypoglycemia | Glimepiride | Day 1 up to Week 104 | 30.2 | percentage of participants | |
| Percentage of Participants With Hypoglycemia | TAK-875 25 mg | Day 1 up to Week 104 | 5.4 | percentage of participants | |
| Percentage of Participants With Hypoglycemia | TAK-875 50 mg | Day 1 up to Week 104 | 5.3 | percentage of participants | |
| Change From Baseline in Body Weight at Weeks 78 and 104 | Glimepiride | Baseline | 84.32 | Standard Error 0.981 | kg |
| Change From Baseline in Body Weight at Weeks 78 and 104 | TAK-875 25 mg | Baseline | 84.55 | Standard Error 1.003 | kg |
| Change From Baseline in Body Weight at Weeks 78 and 104 | TAK-875 50 mg | Baseline | 85.67 | Standard Error 0.995 | kg |
| Change From Baseline in Body Weight at Weeks 78 and 104 | Glimepiride | Change at Week 78 | 1.24 | Standard Error 0.492 | kg |
| Change From Baseline in Body Weight at Weeks 78 and 104 | TAK-875 25 mg | Change at Week 78 | -0.07 | Standard Error 0.524 | kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01481116/results